Turning Point Therapeutics, USA

Cancer targeted therapies


HBM contact: Dr Ivo Staijen / Dr Chandra P. Leo

Company status: public

Turning Point Therapeutics is developing a pipeline of novel cancer drugs designed to overcome resistance to available targeted therapies. The company's lead program is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and other advanced solid tumors. With additional programs underway to address similarly intractable oncogenic drivers, the company is marking a turning point in the way non-hematologic malignancies are treated. 

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171